Main Article Content
Background. Growth hormone therapy for idiopathic short stature (ISS) is a subject of debate, because of the heterogeneous endocrine profile in these children. The purpose of this work was to evaluate the effectiveness of mono- (testosterone enanthate) and combined therapy (testosterone enanthate and recombinant growth hormone) in adolescents with idiopathic short stature. Materials and methods. The examined youths of Uzbek population (n = 46) with constitutional delay in growth and puberty aged 14.8–16.2 years were divided into three groups in accordance with the type of treatment. Results. It was found that recombinant growth hormone (somatropin) therapy (0.033 mg/kg/day) in combination with testosterone enanthate (50 mg once every 21 days) is effective and increases the rate of growth in idiopathic short stature with delayed puberty. Conclusions. Monotherapy with testosterone enanthate at a low dose significantly increases the rate of growth in boys with constitutional delay in growth and puberty, compared with the group without treatment, but is significantly less effective than in the group of combined therapy.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008 Nov;93(11):4210-7. doi: 10.1210/jc.2008-0509.
Bolshova O, Samson O, Sprynchuk N, Muz V, Tkachova T, Antropova O. Idiopathic short stature: Clinical-diagnostic criteria. Klinicna endokrinologia ta endokrinna hirurgia. 2013;(42):52-58. (in Ukrainian).
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res. 2008 Apr;18(2):89-110. doi: 10.1016/j.ghir.2007.11.004.
Binder G, Schwarze CP, Ranke MB. Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone. J Clin Endocrinol Metab. 2000 Jan;85(1):245-9. doi: 10.1210/jcem.85.1.6375.
Hujeirat Y, Hess O, Shalev S, Tenenbaum-Rakover Y. Growth hormone receptor sequence changes do not play a role in determining height in children with idiopathic short stature. Horm Res. 2006;65(4):210-216. doi: 10.1159/000092514.
Goddard AD, Covello R, Luoh SM, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995 Oct 26;333(17):1093-8. doi: 10.1056/NEJM199510263331701.
Attie KM, Carlsson LM, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. J Pediatr. 1995 Aug;127(2):244-50.
Cianfarani S, Liguori A, Boemi S, et al. Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. J Clin Endocrinol Metab. 2005 Nov;90(11):6028-34. doi: 10.1210/jc.2005-0721.
Chaplin JE, Kristrom B, Jonsson B, et al. Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm Res Paediatr. 2011;75(4):291-303. doi: 10.1159/000322937.